KeyBank National Association
GALT icon

KeyBank National Association’s Galectin Therapeutics GALT Stock Holding History

KeyBank National Association’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$161K – 1082
2022
Q1 		$161K Hold
100,000
– – ﹤0.01% 1043
2021
Q4 		$207K Hold
100,000
– – ﹤0.01% 1042
2021
Q3 		$388K Buy
+100,000
New +$339K ﹤0.01% 866

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

KeyBank National Association's GALT Position: Q2 2022 in Review

KeyBank National Association sold out of Galectin Therapeutics (GALT) in Q2 2022, closing a stake of 100,000 shares — an estimated $161K sold.

KeyBank National Association first reported a position in GALT in Q3 2021 and held it in 3 quarters. The position peaked at $388K in Q3 2021. 60 funds tracked by Wall St. Rank hold GALT as of Q2 2022.

  • KeyBank National Association reported no remaining Galectin Therapeutics position as of Q2 2022 after selling out during the quarter.
  • KeyBank National Association sold 100,000 Galectin Therapeutics shares in Q2 2022, an estimated $161K.
  • KeyBank National Association first reported a position in Galectin Therapeutics in Q3 2021 and held it in 3 quarters.
  • KeyBank National Association's Galectin Therapeutics position peaked at $388K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2022.

Based on KeyBank National Association's 13F filing for Q2 2022, filed 8 Aug 2022.